Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Remdesivir

- PMLiVE

Sinovac’s late-stage COVID-19 vaccine trial paused in Brazil

Health regulator Anvisa reports that pause is due to severe adverse event

- PMLiVE

NHS asked to ‘ready’ itself to provide Pfizer’s COVID-19 vaccine

Health Secretary Matt Hancock expects widespread roll-out early next year

- PMLiVE

Eli Lilly’s COVID-19 antibody scores FDA emergency use approval

Drug authorised to treat mild-to-moderate COVID-19

- PMLiVE

Pfizer, BioNTech’s COVID-19 vaccine prevents 90% of infections in initial late-stage study data

Preliminary results could warrant regulatory approval soon

- PMLiVE

Gilead’s remdesivir not included in WHO’s COVID-19 drug scheme

Remdesivir not included as a priority drug, Reuters reports

- PMLiVE

Novartis’ canakinumab failed to improve survival in COVID-19 study

Swiss pharma company had been studying drug in hospitalised COVID-19 patients

- PMLiVE

EMA will assess potential COVID-19 vaccine on ‘case by case’ basis

Agency will not specify a minimum level of efficacy, according to Reuters

- PMLiVE

AZ is expecting late-stage COVID-19 vaccine data this year

Company reiterated timeline in third quarter results

- PMLiVE

NHS gearing up for possible pre-Christmas COVID-19 vaccinations

NHS chief exec said the NHS is getting ready to administer vaccines

AstraZeneca AZ

AZ confirms the UK’s MHRA has started rolling review of its COVID-19 vaccine

Regulatory agency will review data as and when it becomes available

- PMLiVE

CureVac reveals early data for mRNA-based COVID-19 vaccine candidate

German biotech says vaccine demonstrated an immune response in phase 1/2

- PMLiVE

Regeneron halts enrolment of severely ill patients in COVID-19 antibody trial

Trial modified based on recommendations from independent data monitoring committee

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links